Oddly timed to say the least. The AI should surely be able to scour the internet and “understand” the potential for a quick reversal in Cytodyn’s fortunes. I’d argue it was ripe for crushing a year ago but now shorting here carries incredible risk.

Several years ago, Forbes suppressed a pro-Leronlimab article. Not beyond the realm of possibility that it’s in cahoots with AF-types and this was all part of a plan to cover their short positions while leaving followers holding the bag.